Genmab — Juni 2018
-
Daratumumab for the Treatment of Multiple Myeloma - https://www.frontiersin.org/articles/10.3389/fimmu.2018.01228/full
-
"If further substantiated that an implication may be that daratumumab should be part of any anti-myeloma treatment. Given the pleiotropic effects of daratumumab, it is in fact difficult to imagine how a myeloma patient can become truly refractory to daratumumab."
-
Mere fra Journal of Immunology. 1. maj, 2018: Dara i CLL, http://www.jimmunol.org/content/200/1_Supplement/58.17
-
Yes, it looks like Mayo-people all over. Ohio State is currently running a combo with Ibrutinib https://www.clinicaltrials.gov/ct2/show/NCT03447808?term=daratumumab+cll&rank=1
-
Desværre fortsætter stigningen ikke i dag. TA mæssigt, er det vel vigtigt,
vi lukker over kurs 1000. -
hehe
-
Godt klar over at GSK er ugleset her på sitet. Men det var trods alt dem, der udviklede sc ofa. Der ligger 3 IV ofa i RA på CT, som blev afbrudt, fordi man ville gå over til sc. Og 1 gennemført sc i RA. Som herefter Novartis indtil videre har ignoreret.
-
@Bulder, ja, men kan vi ikke også lige blive enige om, at GSK sparkede Ofa til hjørne, helt uden grund?? Meget godt move af Novartis vil jeg mene, tror bare de kun har fokus på MS
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind